Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05987449 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A
A Phase 1 study of Hemophilia A, sponsored by Hoffmann-La Roche.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 13
- Study locations
NCT05987449: Recruiting Phase 1 study of Hemophilia A, sponsored by Hoffmann-La Roche.
NCT05987449 is a Phase 1 study of Hemophilia A that is actively recruiting participants, run by Hoffmann-La Roche. The registered enrollment target is 60 participants, below the 90-participant average among 42 other Hemophilia A trials with a reported enrollment target (33% lower). The trial reports 13 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05987449, a Phase 1 study of Hemophilia A, is actively recruiting participants, sponsored by Hoffmann-La Roche.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 13
- Study locations
Study Summary
WP44714 is a Phase I/II, open-label, non-randomized, global, multicenter trial consisting of two parts: * Part 1 is a multiple-ascending dose (MAD) study in adult and adolescent male participants with severe or moderate hemophilia A with or without factor VIII (FVIII) inhibitors. * Part 2 is a multiple-dose study in pediatric male participants with severe or moderate hemophilia A with or without FVIII inhibitors. The overall aim of the study is to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of NXT007.
Conditions Studied
Interventions
- DRUG NXT007
Study Locations (13)
Other
- Auckland Cancer Trial Centre - Auckland
- Uniwersyteckie Centrum Kliniczne - Gda?sk
- Instytut Hematologii i Transfuzjologii - Warsaw
- Hospital Universitario la Paz - Madrid
- Hospital Regional Universitario Carlos Haya - Málaga
California
- UC Davis Cancer Center - Sacramento
District of Columbia
- Georgetown Uni Medical Center - Washington D.C.
Indiana
- Indiana Hemophilia & Thrombosis center - Indianapolis
Iowa
- University of Iowa Hospitals and Clnics Dept of Pediatrics - Iowa City
British Columbia
- British Columbia Children's Hospital - Vancouver
Ontario
- Hamilton Health Sciences Corporation - Hamilton
Lombardy
- Istituto Clinico Humanitas - Rozzano (MI)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2023-09-21 |
| Est. Completion | 2030-06-16 |
| Phase | Phase 1 |
What NCT05987449 shows while recruiting
NCT05987449 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 90-participant average among 42 other Hemophilia A trials with a reported enrollment target (33% lower).
The record links to 1 condition, with Hemophilia A appearing as the primary indexed condition, and to 1 intervention - of which NXT007 is the first listed.
NCT05987449 lists 13 locations in 9 states (Other, California, District of Columbia).
Frequently Asked Questions
What is clinical trial NCT05987449 about?
NCT05987449 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A". WP44714 is a Phase I/II, open-label, non-randomized, global, multicenter trial consisting of two parts: * Part 1 is a multiple-ascending dose (MAD) study in adult and adolescent male participants with severe or moderate hemophilia A with or without factor VIII (FVIII) inhibitors. * Part 2 is a mult...
What is the current status of trial NCT05987449?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2023-09-21. Estimated completion is 2030-06-16.
What conditions does trial NCT05987449 study?
This clinical trial studies the following conditions: Hemophilia A.
What interventions are being tested in trial NCT05987449?
The interventions under investigation include: NXT007 (DRUG).
Who is sponsoring clinical trial NCT05987449?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05987449 being conducted?
This trial has 13 study locations across California, District of Columbia, Indiana, Iowa, British Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hemophilia A
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05987449's enrollment target sits among peer trials
60 22nd of 42 higher than 21 of 42 other Hemophilia A trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hemophilia A trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A
RECRUITING · Phase 1
-
ASC618 Gene Therapy in Hemophilia A Patients
RECRUITING · Phase 1
-
A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)
RECRUITING · Phase 1
-
Gene Therapy Trial for Platelet Derived Factor VIII Production in Hemophilia A
ACTIVE NOT RECRUITING · Phase 1
-
Gene Therapy for Haemophilia A.
ACTIVE NOT RECRUITING · Phase 1
-
Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a "Shuttle"
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI